Pharvaris to Present at the WSAAI Annual Meeting 2024
ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor…
Pharmaceuticals, Biotechnology and Life Sciences
ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor…
January 26, 2024 – Company announcement no. 1 Please see attachment. Contact information Investor RelationsDisa Tuominen+45 6038 [email protected] Press RelationsSanne…
Please read the full announcement in PDF Attachment 2024_01_All_Regulatory_Approvals_Obtained
ORION CORPORATION PRESS RELEASE 26 JANUARY 2024 at 09.00 EET Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024Orion presented yesterday…
SAN MATEO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing…
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) — Psyence Group Inc (“Psyence Group”), a clinical-stage life science biotechnology company pioneering the…
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its…
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) — Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today…
Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA…
Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval…